Permissions communications

FIG. 2-14 MoUier diagram for nitrous oxide. (Fig. 9, Cfniv. Texas Rep., Cont. DAI-23-072-ORD-685, June 1, 1956, hy Couch and Kobe. Reproduced hy permission.) Some irregularity in the compressibility factors from 80 to 160 atm, 50 to 100 C exists (Couch, private communication, 1.967). See Couch et al.,y, Chem. Eng. Data, 6, (1961) for P -T data. 

Ran Y. Kim, personal communication, 8 April 1981. For additional information, see Ran Y. Kim, On the Off-Axis and Angle-Ply Strength of Composites, in Test Methods and Design Allowables for Fibrous Composites, C. C. Chamis (Editor), Dearborn, Michigan, 2-3 October 1979, ASTM STP 734, American Society for Testing and Materials, 1981, pp. 91-108 (reprinted with permission). 

Fig. 3.4 EPR specti-a of (a) [Ph4P2N3S] and (b) [Ph4P2 N3S] in CH2CI2 [Reproduced with permission from J. Chem. Soc., Chem. Commun., 596 (1986)]...

Figure 4-11. Settler vessel runs full. Adapted by permission, Abernathy, M. W., Vol. 25, Encyclopedia of Chemical Processing and Design, J. J. McKetta, Ed., Marcel Dekker, 1987, p. 77 and Hydrocarbon Processing, Sept. 1977, p. 199 [25] and private communication.

Figure 9-63B. Capacity correlation of structured Intalox 2T. The capacity parameter is at the maximum efficient capacity (MEC) point defined by Rukovena and Koshy [151]. The MEC point is iowerthan thefiood point and iocated where the packing wili maintain its desired efficiency. Used by permission of Rukovena, E. and Koshy, T. D., private communication, and Ind. and Eng. Cham. Res. V. 32, No. 10 (1993) p. 2400 all rights reserved.

Figure 10-121. Hajek correlation thermosiphon reboilers overall coefficients at maximum flux. (Used by permission Hajek, J. D. Private communication. Deceased.)...

Used by permission Peard, R. Private communication, June 1959. York Corp., Houston, Texas. 

Figure 8.10 GPC analysis of poly(l-octenylene) (10) and hydrogenated poly(octenamer) in trichlorobenzene at 135°C. [Reproduced with permission from Macromol. Chem., Rapid Commun. 14, 657-662 (1993). Copyright 1993 Wiley-VCH.]...

The authors acknowledge the permission of various publishing companies and authors for permission to reproduce figures. They acknowledge with gratitude the permission of Shell Research B.V. and of Shell Oil Company to make the results of this study available to the scientific community. 

Requests for permission to conduct clinical trials with pharmaceuticals in the US are termed Investigational New Drug Applications (INDs). The applications are actually a request for an exemption to supply a drug without a marketing authorisation. A cover sheet (Form 1571) must accompany the application. This cover sheet should also be used with each subsequent communication with the FDA, with each form consecutively numbered, starting at 000 for the initial submission. A copy of the form is shovm in Figure 5.6. 

Figure 5.18 Silver-stained two-dimensional gel of the proteins extracted from the yeast S. cerevisiae. From Poutanen, M., Salusjarvi, L., Ruohonen, L., Penttila, M. and KaLkM-nen, N., Rapid Commun. Mass Spectrom., 15, 1685-1692, Copyright 2001. John WUey Sons Limited. Reproduced with permission.

Figure 5.35 Schematic of a system which allows eluates from four HPLC columns to be introduced simultaneously into a mass spectrometer. From de Biasi, V., Haskins, N., Organ, A., Bateman, R., Giles, K. and Jarvis, S., Rapid Commun. Mass Spectrom., 13, 1165-1168, Copyright 1999. John Wiley Sons Limited. Reproduced with permission.

FIGURE 32-2. Treatment algorithm for Alzheimer s disease. A. Cognitive treatment. B. Treatment of psychiatric or behavioral symptoms. AD, Alzheimer s disease MMSE, Mini Mental Status Examination NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer s Disease and Related Disorders Association. (From Faulkner JD, Bartlett J, Hicks P. Alzheimer s disease. In DiPiro JT, Talbert RL, Yee GC, et al, (eds.) Pharmacotherapy A Pathophysiologic Approach. 6th ed. New York McGraw-Hill 2005 1164, with permission.)... 

Figure 1.5 Road map of polymer/additive analysis. Reprinted with permission from LC.GC Europe, Vol. 14, Number 8, August 2001. LC.GC Europe is a copyrighted publication of Advanstar Communications Inc. All rights reserved...

After Leyden and Rabb [68]. Reproduced by permission of Communication Channels Inc. (Argus Press Holdings Inc.). 

After Hasty and Revesz [449]. Reproduced by permission of International Scientific Communications, Inc. 

Figure 4.22 Analysis of dialkyl phthalates using 3-pm 100 A PS/DVB columns. After Meehan and Saunders [758]. Reproduced by permission of International Scientific Communications...

Figure 6.22 FD-MS spectrum of an equimolar mixture of polymer additives. After Jackson et al. [96]. Reprinted from A.T. Jackson et al., Rapid Communications in Mass Spectrometry, 10,1449-1458 (1996). Copyright 1996 John Wiley Sons, Ltd. Reproduced with permission...

Surface impoundment treatment exemptions Surface impoundment treatment exemptions allow the regulated community to petition U.S. EPA for permission to treat hazardous waste in surface impoundments. Under normal circumstances, owners and operators cannot place untreated hazardous waste on the land, even if it is in a land-based unit for treatment. Since many facilities use surface impoundments as a means of treating waste, the surface impoundment treatment exemption allows owners and operators to conduct such treatment under certain conditions. Surface impoundments treating waste under this exemption must comply with double liner and minimum technical requirements, and provisions for the removal of sludges and treatment residues. 

---